MGI Tech Co., Ltd. ("MGI"), a business dedicated to creating essential tools and technologies that spur life science innovation, is pleased to announce that its exclusive DNBSEQ sequencing technology has been on the market for ten years. DNBSEQTM has revolutionized the genomics field over the last decade by providing high-performance, affordable sequencing tools that enable researchers, scientists, and physicians worldwide.
Since its initial commercial debut in 2015, DNBSEQ has grown to become a reliable platform for state-of-the-art research and diagnostics, with over 3,900 installations globally and over 10,900 peer-reviewed publications* to its credit. DNBSEQ is still at the vanguard of sequencing innovation today, propelling advancements in a variety of fields, including precision medicine, public health, agriculture, biodiversity, and more.
A Decade of Innovation at Scale and Speed
With the use of designed arrays and exclusive DNA nanoball (DNB) technology, DNBSEQ produces high-quality data at a much reduced cost by offering remarkable precision, reduced duplication rates, and little index hopping. It is the perfect option for sensitive clinical applications as well as extensive research because of these benefits.Users have frequently lauded DNBSEQ technology for its exceptional data quality and affordability in a variety of applications, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES). Additionally, studies have found the platform to be a great option for metagenomic sequencing, bacterial genome research, eukaryotic genome sequencing, and other applications, proving its adaptability and dependability in a variety of settings.
With the broadest range of sequencing throughput and application coverage available in the market, DNBSEQTM has completely changed the pace of genomic technology innovation. The ultra-high-throughput DNBSEQ-T20×2 that produced the first human genome under $100, the widely used DNBSEQ-T7 for high-throughput versatility, the ultra-compact DNBSEQ-E25 for fieldwork and decentralized testing, the benchtop DNBSEQ-G400, and the fastest in its class for mid-to-low throughput sequencing, the DNBSEQ-G99, are just a few of the genetic sequencers based on DNBSEQä that MGI offers today under the T, G, and E series. The DNBSEQ-T1+, MGI's newest flagship, is an ultra-fast benchtop sequencer that strikes a balance between power, speed, and flexibility. It demonstrates MGI's unwavering dedication to continual innovation by enabling scientists to speed up discoveries without sacrificing quality.
Facilitating Multi-Omics and Practical Effects
DNBSEQTM is more than just a sequencing platform; it makes a variety of multi-omics applications possible, such as single-cell, transcriptomic, genomic, epigenetic, and spatial omics. These features make it an effective tool for a variety of scientific domains, allowing for a deeper understanding of biological systems, environmental connections, and disease causes.
From the depths of the Mariana Trench to the summit of Mount Everest, DNBSEQ has been proven to produce dependable, high-quality findings anywhere research needs to go.
Complete Solutions: Simplifying Science
A range of automation and BIT tools from MGI enhance its sequencing platforms, providing a smooth end-to-end workflow from sample preparation to data interpretation. Regardless of lab size or location, these integrated solutions increase efficiency, decrease manual labor, and make cutting-edge genomic tools accessible to more users.
MGI's technology ecosystem is built to eliminate obstacles and save expenses, allowing researchers to concentrate on discovery rather than complexity. This approach was motivated by the idea, "What if science had no barriers?"
Moving Toward a More Equitable Future with the $10 Genome
MGI is concentrating on reaching its most ambitious objective to date: the $10 genome, as it looks to the future. MGI is creating next-generation sequencing technologies to further lower prices, improve accessibility, and speed up time to insight, building on the foundation of DNBSEQ.
"DNBSEQ™ has evolved over the last ten years from an innovation to a global standard for high-quality, cost-effective sequencing," stated MGI Chief Scientific Officer Dr. Rade Drmanac. "We've opened doors for researchers everywhere—and now, we're building the next chapter in accessible genomics."
Genomics for All: The Pursuit Goes On
More than just a technological achievement, marking ten years of DNBSEQTM is a reaffirmation of MGI's aim to make genomics impactful, affordable, and accessible to everyone. One genome at a time, MGI is contributing to the creation of a more connected, healthier, and knowledgeable world by providing the resources that spur discovery.
About MGI
Building essential tools and technologies that spur innovation in life science is the primary mission of MGI Tech Co., Ltd. (or its subsidiaries collectively referred to as MGI). We specialize in the creation, production, and marketing of tools, chemicals, and associated goods for the life sciences and biotechnology industries.For precision medicine, agriculture, healthcare, and other industries, we offer a wide range of digital equipment and systems that are multi-omics and real-time.Since its founding in 2016, MGI has developed into a world leader in the life sciences, with facilities for research, manufacturing, training, and after-sales support spread across six continents. One of the few businesses that can independently design and manufacture clinical-grade gene sequencers in large quantities with different throughput capacities, from Gb to Tb levels, is MGI. MGI continues to influence the future of life sciences with its unmatched experience, innovative products, and dedication to global impact. Please visit Linkedin, X, YouTube, and https://en.mgi-tech.com/ to find out more.